We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement

Product News   May 04, 2020

 
COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement

Credit: rawpixel

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Immune Responsive Nanoparticles for COVID-19 Vaccine Delivery

Product News

Analytik reports how the Quadram Institute has invested in a ZetaView Nanoparticle Tracking Analyser to help them develop a new approach for vaccine delivery based on engineering the natural ability of resident gut bacteria to generate nanoparticle sized Outer Membrane Vesicles.

READ MORE

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE